Targeted Dna Rna Sequencing Market Size Projected to Reach $44.55 billion by 2034 | 18.98%

According to Straits Research, the global targeted DNA RNA sequencing market size was valued at $9.35 billion in 2025 and is projected to grow from $11.09 billion in 2026 to $44.55 billion by 2034, registering a CAGR of 18.98% during the forecast period 2026–2034.

Market Dynamics

The targeted DNA RNA sequencing market continues to expand as research institutes, healthcare systems and biopharma organizations incorporate focused genomic assays into diagnostic and discovery workflows. A key driver for this growth is the accelerating integration of targeted sequencing in precision medicine programs, where clinicians rely on defined genomic and transcriptomic regions to guide treatment selection, monitor disease progression, and characterize patient-specific molecular patterns. This increases demand for customizable panels, streamlined library preparation workflows, and advanced data interpretation tools across clinical and translational research settings. However, a restraint affecting market progression is the challenge of maintaining uniform assay performance across laboratories with varying sequencing platforms, workflow structures, and computational capabilities. Differences in library preparation conditions and sample quality can influence dataset consistency, creating additional validation requirements for institutions participating in large collaborative projects. Despite this, the market presents a substantial opportunity through the rise of spatial and single-cell targeted sequencing platforms that enable high-resolution interrogation of gene activity within localized tissue environments. These emerging approaches support advanced disease mapping, microenvironment analysis, and developmental biology investigations, opening new pathways for panel development, specialized reagent design, and computational innovation across the targeted sequencing ecosystem.